You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeted therapies in breast cancer: are heart and vessels also being targeted?
|
|---|---|
| Published in |
Breast Cancer Research, June 2012
|
| DOI | 10.1186/bcr3142 |
| Pubmed ID | |
| Authors |
Carmen Criscitiello, Otto Metzger-Filho, Kamal S Saini, Gilberto de Castro Jr, Marie Diaz, André La Gerche, Evandro de Azambuja, Martine J Piccart-Gebhart |
| Abstract |
The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of cardiovascular events. The anti-HER2 agents trastuzumab and lapatinib may cause left ventricular dysfunction or even congestive heart failure. Bevacizumab, an antiangiogenic drug, has been shown to increase the risk of hypertension, cardiovascular dysfunction and thromboembolic events. In addition, several anti-human epidermal growth factor receptor 2 (HER2) and antiangiogenic agents plus their combinations are currently being developed and evaluated for the treatment of breast cancer. In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 28% |
| Student > Master | 7 | 18% |
| Student > Bachelor | 6 | 15% |
| Student > Ph. D. Student | 5 | 13% |
| Other | 3 | 8% |
| Other | 4 | 10% |
| Unknown | 4 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 35% |
| Biochemistry, Genetics and Molecular Biology | 5 | 13% |
| Agricultural and Biological Sciences | 5 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Psychology | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 6 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2012.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Breast Cancer Research
#1,705
of 2,052 outputs
Outputs of similar age
#138,994
of 177,903 outputs
Outputs of similar age from Breast Cancer Research
#36
of 42 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,903 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.